Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
NCT06697301Phase 2/3Recruiting
- Lead sponsor
- Eikon Therapeutics (Industry)
- Enrollment
- 740 (estimated)
- Start date
- 22 May 2025
- Primary completion
- Dec 2035 (estimated)
- Study completion
- 1 Dec 2040
- Last update posted
- 6 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 3
Interventions
- EIK1001 Drug
- Pembrolizumab (KEYTRUDA® ) Drug
Conditions and primary outcome
- Advanced Melanoma
Primary outcome
Progression Free Survival (PFS) (up to 5 years); Overall survival (OS) (up to 5 years); Objective Response (OR) (Dose Optimization Only) (up to 5 years); Adverse Events (AEs) (Dose Optimization Only) (up to 2.5 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06697301.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06697301 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.